Q32 Bio Profit Margin

Q32 Bio (QTTB) currently reports a profit margin of 62.87% as of June 2026. That is above the Healthcare sector average of 13.89%. Use the charts on this page to explore Q32 Bio's profit margin history and peer comparisons.

Q32 Bio's profit margin of 62.87% is higher than the Healthcare sector average of 13.89%. That is roughly 352.5% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Q32 Bio's current 62.87% should be judged against Healthcare norms (sector average: 13.89%) and against QTTB's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of 62.87%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 13.89%. From there, open related valuation or income-statement pages for Q32 Bio, and consider following QTTB for alerts when major investors trade the stock.

Q32 Bio is classified in the Healthcare sector. On profit margin, it currently shows 62.87% versus a sector average near 13.89%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing QTTB with unrelated industries.